Breast cancer experience of the molecular tumor board at the University of California, San Diego moores cancer center

Journal of Oncology Practice

Volumn 11, Issue 6, 2015, Pages 442-449

  Parker, Barbara A ^a   Schwaederlé, Maria ^a   Scur, Michael D ^a   Boles, Sarah G ^a   Helsten, Teresa ^a   Subramanian, Rupa ^a   Schwab, Richard B ^a   Kurzrock, Razelle ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; B RAF KINASE; BRCA2 PROTEIN; CRK LIKE PROTEIN; CYCLIN D1; CYCLIN D2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR 3; FIBROBLAST GROWTH FACTOR 4; FIBROBLAST GROWTH FACTOR RECEPTOR 1; K RAS PROTEIN; MYC PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NOTCH1 RECEPTOR; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE CATALYTIC SUBUNIT ALPHA; PROGESTERONE RECEPTOR; PROTEIN; PROTEIN P53; PROTEIN RET; TRANSCRIPTION FACTOR GATA 3; UNCLASSIFIED DRUG; UNINDEXED DRUG; UVOMORULIN; ZINC FINGER PROTEIN 217;

ADULT; ADVANCED CANCER; ARTICLE; BIOINFORMATICS; BREAST CANCER; CANCER CENTER; CANCER REGRESSION; CANCER THERAPY; CHROMOSOME ABERRATION; CLINICAL ARTICLE; FEMALE; FOLLOW UP; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; GENETIC SCREENING; GENOMICS; HEALTH CARE ACCESS; HUMAN; MEDICAL SOCIETY; MEDICAL SPECIALIST; METASTASIS; MOLECULAR DIAGNOSIS; MOLECULAR TUMOR BOARD; NEXT GENERATION SEQUENCING; PATIENT CARE; PHYSICIAN; POINT MUTATION; PROGRESSION FREE SURVIVAL; SCIENTIST; TREATMENT RESPONSE; UNIVERSITY HOSPITAL; BREAST NEOPLASMS; CALIFORNIA; CERTIFICATION; DISEASE FREE SURVIVAL; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED;

BREAST NEOPLASMS; CALIFORNIA; CANCER CARE FACILITIES; DISEASE-FREE SURVIVAL; FEMALE; GENETIC TESTING; HOSPITALS, UNIVERSITY; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; SPECIALTY BOARDS;

EID: 84947216680     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2015.004127     Document Type: Article

References (26)

1. Manyika J, Chui M, Bughin J., et al: Disruptive technologies: Advances that will transform life, business, and the global economy. McKinsey Global Institute Report, 2013
2. Vasan N, Yelensky R, Wang K., et al: A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: Implications for clinical practice. Oncologist 19: 453-458, 2014
3. Wheler JJ, Parker BA, Lee J.J., et al: Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms. Oncotarget 5:2349-2354, 2014
4. Santarpia L, Qi Y, Stemke-Hale K, et al: Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Res Treat 134:333-343, 2012
5. Shi W, Balazs B, Györffy B, et al: Combined analysis of gene expression, DNA copy number, and mutation profiling data to display biological process anomalies in individual breast cancers. Breast Cancer Res Treat 144:561-568, 2014
6. Wheler J, Lee JJ, Kurzrock R: Unique molecular landscapes in cancer: Implications for individualized, curated drug combinations. Cancer Res 74:7181-7184, 2014
7. Schwaederlé M, Parker BA, Schwab RB, et al: Molecular tumor board: The University of California-San Diego Moores Cancer Center experience. Oncologist 19:631-636, 2014
8. FoundationOne. http://foundationone.com/
9. Huang X, Gollin SM, Raja S, et al: High-resolution mapping of the 11q13 amplicon and identification ofa gene, TAOS1, that is amplified and overexpressed in oral cancer cells. Proc Natl Acad Sci U S A 99:11369-11374, 2002
10. Schwaederlé M, Daniels GA, Piccioni DE, et al: Cyclin alterations in diverse cancers: Outcome and co-amplification network. Oncotarget 6:3033-3042, 2014
11. Tai W-T, Shiau C-W, Chen H-L, et al: Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells. Cell Death Dis 4:e485, 2013
12. Dargart JL, Fish K, Gordon L.I., et al: Dasatinib therapy results in decreased B cell proliferation, splenomegaly, and tumor growthin amurine model of lymphoma expressing Myc and Epstein-Barr virus LMP2A. Antiviral Res 95:49-56, 2012
13. Aguirre D, Boya P, Bellet D., et al: Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma. Apoptosis 9:797-805, 2004
14. Janku F, Wheler JJ, Westin S.N., et al: PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 30:777-782, 2012
15. Janku F, Hong DS, Fu S, et al: Assessing PIK3CAand PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep 6:377-387, 2014
16. Hortobagyi G, Piccart-Gebhart MJ, Rugo H.S., et al: Correlation of molecular alterations with efficacy of everolimus in hormone-receptor-positive (HR+), HER2-negative advanced breast cancer: Preliminary results from BOLERO-2. J Clin Oncol 31:9s, 2013 (suppl; abstr LBA509)
17. Von Hoff D.D., Stephenson JJ Jr, Rosen P, et al: Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments fortheir refractory cancers. J Clin Oncol 28:4877-4883, 2010
18. Robinson DR, Wu Y-M, Vats P, et al: Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet 45:1446-1451, 2013
19. Weis KE, Ekena K, Thomas J.A., et al: Constitutively active human estrogen receptors containing amino acid substitutions fortyrosine 537 in the receptor protein. Mol Endocrinol 10:1388-1398, 1996
20. Toy W, Shen Y, Won H., et al: ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet 45:1439-1445, 2013
21. Karlsson E, Waltersson MA, Bostner J, et al: High-resolution genomic analysis of the 11q13 amplicon in breast cancers identifies synergy with 8p12 amplification, involving the mTOR targets S6K2 and 4EBP1. Genes Chromosomes Cancer 50:775-787, 2011
22. Soria J-C, De Braud F, Bahleda R, et al: Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors. Ann Oncol 25:2244-2251, 2014
23. Hall MJ: Conflicted confidence: academic oncologists' views on multiplex pharmacogenomic testing. J Clin Oncol 32:1290-1292, 2014
24. Gray SW, Hicks-Courant K, Cronin A., et al: Physicians' attitudes about multiplex tumor genomic testing. J Clin Oncol 32:1317-1323, 2014
25. Zardavas D, Baselga J, Piccart M: Emerging targeted agents in metastatic breast cancer. Nat Rev Clin Oncol 10:191-210, 2013
26. American Society of Clinical Oncology: Targeted Agent and Profiling Utilization Registry Study. www.asco.org/practice-research/targeted-agent-and-profiling-utilization-registry-study